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The influence of en re and 
atrices 
Achim Giipferich and Geoffrey Lee 
The influence of an endogenous surfactant present in Eudragit NE30D on the structure and drug 
release (clenbuterol) properties of thin matrices has been examined. Both drug-free and drug-loaded 
matrices were found to be non-isotropic in structure, the former having a marbled appearance under 
the polarising light microscope, and the latter showing numerous needle-shaped crystals. At loading 
above approx. 10% w/w clenbuterol it was also possible to observe aggregates of the drug. Differential 
scanningcalorimetry enabled the ide,ntiticatioo fmeltingpeaks at approx. 50°C for the needle-shaped 
crystals and approx. 80°C for the larger drug aggregates. The former are composed of a surfactant used 
by the manufacturer for the synthesis of Eudragit NE3OD by emulsion polymerization. This surfactant 
undergoes a phase separation from the polymer oo storage at room temperature. It could, however, be 
extracted from the polymer hy refluxing in water to yield an isotropic system. The extract showed a 
melting peak at SO’C and also UV, IR, NMR, and mass spectra in accordance with an o-substituted 
nonyl phenol surfactant. Matrices prepared from the purified Eudragit NE30D showed drug release 
rates of only one third the magnitude of those found with matrices prepared from the raw polymer. 
Substantially reduced scatter in the release data was also found with the purified polymer. 
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We have been interested for some time in the 
use of Eudragit NE30D as a carrier for the sus- 
tained release of drugs. Matrix-type carriers can 
easilv be oreoared from thin films ofthe rx4vmer . . . _ , 
cast by solvent evaporation [ I 1. The rate of re- 
lease of the drug clenbuterol from such matrices 
has heen examined using a simple diffusion cell 
121. The accurate valuation ofthe kinetic data 
so obtained requires, however, knowledge ofthe 
mechanism of drug release from the polymer. Of 
elemental importance in this respect is tbe phys- 
ical state of the drug within the polymer matrix, 
as the release kinetics depend inter alia on 
whether the drug exists in the dissolved or sus- 
pended condition [3]. We deemed it expedient, 
therefore, to determine the solubility of the cleo- 
buterol in the Eudraait NE30D. To that end an 
examination of d&loaded polymer matrices 
was undertaken using polarising light micros- 
copy. We were surprised to observe that the ma- 
trices were strikingly anisotropic in structure, 
showing either a marbled appearance or the 
preseoce of variously-shaped crystals and fractal 
aggregates. Indeed, it was not possible to distin- 
guish unequivocally between drug crystals and 
the other snuctures observed. We found little in- 
formation in the literature concerning the strut- 
ture of Eudragit NE30D. despite its use to pro- 
duce matrix tablets as a drug carrier [4]. Only 
two differential scanning calorimetric studies of 
Eudragit NE30D [ 51 and the related Eudragit 
7972-55 PMMA ON [6] have been published. 
neither of which offered a satisfactory explana- 
tion of our observations. 
It soon became clear from further experiment 
that the puzzlicg microscopical appearance ofthe 
matrices was a result of the presence of small 
amounts of a water-soluble contaminant within 
the Eudragit NE30D. This is almost certainly a 
surfactant used by the manufacturer for the syn- 
thesis of the polymer by emulsion polymeriza- 
tion [7a]. It was possible to remove this endog- 
enous contatninant from the polymer by 
extraction with water to yield ao isotropic sys- 
tem. We present in this paper our findings con- 
cerning the effects of the endogenous urfactant 
on the physical state of clcilbuterol within the 
Eudragit NE30D-matrices and the consequences 
for drug release rate which ensue from its 
removal. 
The basic drug clenbuteroi of molecular weight 
277 and pKa 9.5 was used as received from 
Baehrinpr lngelheim KG (Ingelheim, 
Germany): 
+ 
Eudragit NE30D (Riihm, Weiterstadt, Ger- 
many) is a neutral, poly(ethylacrylate-methyl- 
methacrylate) copolymer with a molecular 
weight of approx. 800,000, and which exists in 
the rubbery stat? at room temperature (glass 
transition at -8’C): 
CH3 
..-CH,-CH-CH,-ti-... 
LO 
&IF dCH> 
Although insoluble at all pHs, it swells in water. 
It was obtained as a 30% aqueous dispersion and 
freeze dried at -25°C to yield a white solid. All 
solvents and buffer salts were pA grade. Water 
was double-distilled from an all-glass apparatus. 
Experimental methods 
Preparation of E&&t NEJQD-matrices 
Films of 50 pm thickness containing various 
concentrations of clenbuterol in the range O-20% 
w/w were prepared on a siliconized paper base 
by the casting of a 15% w/w acetone sulution of 
the raw polymer. The product was dried at room 
temoerature for 12 h. after which less than 50 
pp& acetone remained as determined by gas 
chromatography. Round matrices (Qr2 cm) were 
then cut from the film using a punch. 
According to the manufacturer, Eudragit 
NE3QD contains traces of a water soluble, neu- 
tral surfactant ofthe “owl-ahenol-twe IYbl. We 
attempted to extract the surfactant from Eudra- 
git NE30D by refluxing the freeze-dried polymer 
in a Soxlct for 90 h with water. The resulting pur- 
ified polymer was a white solid. The dried ex- 
tract took the form of a yellowish-white, crystal- 
line solid, which was found to represent approx. 
3.3% of the total mass of the dried raw oolvmer. 
Matrices of the purified Eudragit NEiOdwere 
then prepared as described above, also contain- 
ing concentrations ofclenbuterol in the range O- 
20% w/w. 
Polarisin light microscopy 
The matrices were examined at various times 
after their preparation using a Zeiss Standard 
microscope fitted with a polarizing objective and 
condenser, ahot stage for examining thermal be- 
haviour, and a Nikon C35 camera. The extract 
and pure clcnbuterol were also examined. 
DifferenIial scanning calorimetry (
A Mottler model TCIOA (Greifcnsee, Swiiz- 
erland) was used to examine the matrices at vu- 
ious times after their preparation, as well as the 
extract and pure clenbuterol. A heating/cooling 
speed of IO K/min was selected. 
UV, IR and mass ~~ect~o~hoto~etry; NMR
An attempt was made to confirm ifthe crystal- 
line extract obtained from the raw polymer coo- 
tained a surfactant of the type declared by the 
manufacturer. To that end, WV (Zeiss DMR 21 ),
IR (Beckman Aculab 6), and mass spectropho- 
tometry were employed. 250 MHz-NMR spectra 
were also obtained in D,O. In all cases the solid 
extract was firsi recrystallized from methanol to 
remove any inorganic contaminants. 
Measurement of dmg release 
The release ofclenbuterol out of matrices pre- 
pared from both raw and p&lied Eudragit 
Rg. I. Photographs al E-days’ old matrices prepared from raw Eudragit NE30D viewed under crossed polariacn; (a) drug-free, 
(b) 6% wlwdrug (clenhuteml) loading, (c) 12% drug loadmg. Cd) 20% drugloading. 
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NE30D into pH 8 phosphate buffer VW mea- diffusivityofclenbuterol in the matrices was then 
sured at 35°C using an all-glass diffusion cell of calculated by fitting each release profile to a nu- 
standard design [ 21. Tbe results were expressed merical solution to the diffusion equation undu 
as release profiles of m(r)/A versus time, where non-sink conditions, as described in detail else- 
WI(~) is the mass of clenbuterol in the acceptor where [ 21. Of relevance to this study is that the 
medium at time I and A is the release area. The solut?m assumes the linear diffusion of drug with 
h#emlo 
1 
l/20% 
32/o% 
served directly under the microscope. Accord- 
ingly, this peak is not seen on the scans for ma- 
trix containing 6% clenbuterol, where tbe 
microscopy resdhs indicate that the drug is fully 
dissolved, or the drug-free matrix. Witb ah the 
matrices examined, however, aclear endother- 
mic peak is visible at apurox. 50°C. For tbe drug- 
free matrix, this peak develops slowly on storage, 
first appearing clearly after 8 days. Simultaue- 
ousfy the marbled areas become noticeable within 
this matrix. AI1 of the d~g~ootaioinS matrices 
show a clear peak even after the first day‘s stor- 
age. The needle-shaped crystals can be observed 
to grow correspondingly. This endothermic peak 
is, therefore, clearly not caused purely by the ex- 
istence of drug within the polymer, developing 
even for the drug-free matrix, albeit more slowly. 
The existence ofsuch an endothermic peak has 
already been noted in the literature [6] and as- 
signed to a glass transition ofthe polymer at this 
temperature. Furthermore, there exists a pro- 
posal (5 1. also based on the results of DSC mea- 
suremems, that crystalline structure xists within 
Eudragit NE3QD. It is not, however, possible to 
reconcile the results ofour experiments with this 
earlier work. Thus, the DSC-scan for the drug- 
free matrix prepared from the purified Eudragit 
NE30D shows no signs 01 an endothermic tran- 
sition at 5O”C, eve* after storage at room tem- 
perature for 128 days (Fig. 3). The tbe~ogmm 
for the crystailine solid extracted from the En- 
dragit NE3OD (Fig. 4). however, cieariy shows 
such a peak at 5O’C, corresponding tothe melt- 
ing point of thrs extract as observed under the 
light microscope. When a drug-free matrix pre- 
pared from the purified Eudragit NE30D is 
viewed under the light microscope an isotropic 
system is seen (Fig 5a); the marbled areas ob- 
served nithin the raw polymer are not present 
and do not developon storage. Furthermore, the 
matrix prepared fmm the purified Eudragit 
NE30D and containing 6% clenbuterol (Fig. Sb) 
shows neither drug nor needle-shaped crystals 
and its DSC-scan has no visible peaks (Fig. 3). 
With 12 and 20% drug load&g the usual crystal 
and fractal forms of the drug can be observed un- 
constant diffusivity, D, in a iinile, isotropic, 
planematrix withspontaneous partitioning at all 
boundaries. The initial condition used specifies 
the existence only of dissolved rug. 
When viewed under the light microscope with 
crossed polarizers the raw Eudragit NE3OD-ma- 
trices reveal a complex structure that depends on 
time elapsed since preparation and drug-load- 
ine. A stable nicture tirst emeraes after 6-8 davs’ 
storage at room temperature. ?his is illustraied 
by the photographs taken of &days old Eudragit 
NE30Dmatrices having selected loadings ofO%, 
VI&, 12%. and 20% w/w clenbuterol (Fig. la-d, 
respectively). Thus, the two matrices of highest 
drug loading clearly show a population of large, 
irreguiarly-shaped crystals, ome ofwhieh are not 
euclidian but rather of fractal shape. These were 
observed to melt when the temperature was 
raised to approx. SO-90°C. and certainly come 
from the incorporated rug, even though this 
melting poiat lies well beiow that of pure clen- 
buteroi f 135 “Ct. Careful sc~tinjzation of these 
two photo~aphs also reveals the presence of a 
second tvue of much smaller. needle-shaued 
crystal, w&h melted at approx: 50°C. The ma- 
trix containing only 6% w/w clenbuteroi (Fig. 
lb) shows none of the large crystals or fractal 
forms, indicating that the drug is soluble in the 
polymer at this concentration. The needle-shaped 
crystals are, however, still cleady visible at this 
drug loading. Although they do not appear within 
the drug-free matrix (Fig Ia), the polymer has 
a distinctly marbled appearance under crossed 
polar&em and is thus also anisotropic. 
The DSC-scans for these matrices (i=ii. 2) at 
12% and 20% drug loading both develop on stor- 
age a slight endothermic transition at approx. 
80°C. This coincides with the melting of the large 
crystals and fractal aggregates ofdrug within the 
polymer at this temperature, as could be ob- 
Fig 3. USC-scans of clmburorol-ioadcd, purified Eudragit NE30D matrices taken I and 32 days alter their preparation. Key: 
day/dmgiosding f%l. 
der the microscope (Fig. 5c,d ). but again none 
of the needle-shaped crystals. The DSCscans 
show only the slight melting peaks for the drug 
crystals and aggregates at8%90°C and no en- 
dothermic transition at 5O’C (Fig. 3). 
On the basis of these results it appears that the 
endothermic transition observed at approx. 50°C 
for the raw Eudragit NE30D arises from the 
phase separation of some water-soluble, endoge- 
nous substance within the polymer. At this point 
we must bear in mind the manufacturer’s decla- 
ration that Eudragit NE300 contains traces of a 
water-soluble, o-substitute nonyl-phenol sur- 
fact& having a molecular weight of 5000-600~ 
[7b]. The spectroscopic data we obtained from 
the extract provides evidence to suggest that the 
extract contains such a surfactant. Thus, the 
strong UV-absorbance of the extract at 247 nm 
T I’CI 
Fig. 4. DSGscan olcrjslallinr solid extracted from raw Eudragit NE30D. 
(Fig. 6a) indicates a substituted aromatic struc- 
ture. The band seen in the IR spectrum (Fig. 6b) 
at 2900 cm-’ comes from C-H vibrations, whilst 
that at 830 cm-’ can be assigned to out-of-p:aae 
vibrations of an o-substituted aromatic. Further- 
more, the large band at 1100 cm-’ indicates a 
large content of C-O groups, as would arise from 
a high degree of ethoxylation ofthe molecule. The 
three major peaks of the mass spectrum (Fig. 6c) 
occur at 45 m/e. 89 m/e and 133 m/e. the dif- 
ference betwedn kach bking always 44’udits. This 
finding can be explained if etboxy chains arc 
broken up into units of [-CH2-O-C2H2-1. The 
NMR spectrum (Fig. 6d) can be used to esti- 
mate the ratio between aromatic protons (peaks 
at 6.8 and 1.2 ppm ) and protons originating from 
the supposed ethoxy groups (peak at 3.7 ppm). 
A value of approx. 100-150 ethoxy units is ob- 
tained. Although these spectra are not suf&ient 
per se to allow an unequivocal identification of 
the substance, it seems very probable. Any in- 
compatibility of this substance with the poly- 
acrylats - by virtue of tbe former’s hydrophilic- 
ity - would lead to a phase separation from the 
polymer on storage. In a drug-free matrix this re- 
sults in the marbled appearance of the polymer 
illustrated in Fig. la. The presence of drug within 
the matrix evidently causes the surfactant to 
crystallize out rapidly as needle-shaped crystals 
(cf. Fig. lb). 
Drug release from Eudragit NE3(ID_matrices 
The extraction of the endogenous contami- 
nant from Eudragit NE30D affects the rate of re- 
lease of clenbuterol from the matrices. Fig. 7a ii- 
lustrates for the example of 8% drug-loading how 
the release profiles for the matrices prepared from 
the purified Eudragit NESOD are much lower 
tban those for the matrices prepared from the raw 
Fig. 5. Pholagrwbs oi &days old marices prepared from punii.?d Eudragit NE30D viewed under crossed polarisers; (a) drug- 
free, (b) 6%w/wdrug tclenbutcrol) loading, (c) 12%drugloading, (d) 2O%dmgloadmg. 
Eudragit NE30D (latter taken from ref. 2). The 
diffusivities calculated from the individual pro- 
tiles are concentration-dependent for both mw 
and purified Eudmgit NE30D-matrices (Fig. 
7b). Increasing diffusivity with greater drug 
loading has already been observed for the non- 
extracted polymer [ I,2]. The subsequent dc- 
crease observed here at high drug loading is read- 
ily explained by the influence of the presence of 
substantial ammmls of suspended rug within the 
polymer. For the calculation of diffusivity from 
the release profile, the concentration of drug in 
the matrix must be specified [2], all ofwhich is 
assumed to exist in the dissolved state. In the 
presence of suspended rug, this value will be 
overestimated and cause an underestimation in 
Ihe calculated diffusivity. 
Fig. 7bak.o illustrates that the diffusivities for 
the purified Eudragit NE30D-matrices are about 
I/3 of the magnitude of those for the raw Eudra- 
git NESOD-matrices (latter also taken from ref. 
2). The degree of scatter in the diffusicities ob- 
E 
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FL& 7. (a) Drng release prcdilcs for clcnbulcrol from raw and purJicd Eudragit NESOD-malrws wh 8% w&drug ioading; (b) 
calculalcd diflusivities for clenbuwrol in raw and purified Eudmgit NE3OD-malrices as a function of drug loading tmalrix 
Ihtckncss=50pm). 
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tained is also of note, being strongly dependent 
on drug loading. At the lowest drug loading of 
the raw Eudraeit NE30D we find a coefficient of 
variation (Cv) for the diffusivity of approx. 
10%. which increases sharply with greater dmg 
loading. After reaching some 75Yo for 13% drug 
loading, the CV then falls to approx. 23% at the 
highest drug loading examined. The CVs for the 
diffusivities for the purified Eudragit NE30D- 
matrices do not show this same dependence on 
drug loading. They are fairly constant in value. 
never being more than appron. 10-19/o for any 
of the drug loadings examined. The more scat- 
tered release orotiles and diffusivities obtained 
for the raw E’udragit NE30Dmatrices are per- 
haps not surprising considering the evident un- 
controlled nature of the phase separation of the 
contaminant within the polymer. Assuming that 
this contaminant is the stated surfactant, then the 
mechauism by which its presence leads to greater 
drug release rates may be related to improved 
wettingofthe matrix surface orgreater water op- 
take into the matrix. It is. however, of note that 
the presence of such a small quantity (approx. 
3%) ofthis cndogenous conlaminant has such a 
strong influence on the rate of drug release. 
Conclusiotls 
Matrices prepared from thin films of Eudragit 
NE30D arc anisotropic systems due to the pres- 
ence of a chase-separated. water-soluble con- 
taminant that is incompatible with the polymer. 
This is in all probability an o-substituted nonyl 
phenol surfactant used during the manufacture 
ofthe polymer. The removal ofthis surfactant by 
a simple aqueous extraction process yields an 
isotropic material. Although the rate of drug re- 
lease (clenbuterol) is thereby reduced by almost 
two thirds in magnitude, the degree of scatter in 
both the release profiles and calculated diffusiv- 
ities within the matrix is substantially improved. 
We thank Boehringer Ingelheim KG for its 
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